Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade

References

• Vincent JL, Rello J, Marshall J, . International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323–2329.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503–535.
   PubMed Web of Science ®Google Scholar
• Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O. Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010; 14: R98.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, . Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149–3154.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, . Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532–538.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Sorrell TC, Marriott D, . Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042–1051.
   PubMed Web of Science ®Google Scholar
• Martin D, Persat F, Piens MA, Picot S. Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001. Eur J Clin Microbiol Infect Dis 2005; 24: 329–333.
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Andes D, and the CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164–176.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D and CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180–195.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Andes D, Arendrup MC, . Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330–343.
   PubMed Web of Science ®Google Scholar
• Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445–452.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954–966.
   PubMed Web of Science ®Google Scholar
• Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin 2009; 25: 1732–1740.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142–151.
   PubMed Web of Science ®Google Scholar
• Horn DL, Neofytos D, Anaissie EJ, . Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695–1703.
   PubMed Web of Science ®Google Scholar
• Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59: 360–365.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010; 14: 244.
   PubMed Web of Science ®Google Scholar
• Guery BP, Arendrup MC, Auzinger G, . Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55–62.
   PubMed Web of Science ®Google Scholar
• Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184–190.
   Google Scholar
• Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. Value of (1-3)-β-d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect 2011; 17: 1549–1553.
   PubMedGoogle Scholar